Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.

Antiviral research

Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ.
PMID: 34826506
Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23.

AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC

Cite
Mani N, Cole AG, Phelps JR, et al. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021;197:105211doi: 10.1016/j.antiviral.2021.105211.
Mani, N., Cole, A. G., Phelps, J. R., Ardzinski, A., Burns, R., Chiu, T., Cuconati, A., Dorsey, B. D., Evangelista, E., Fan, K., Guo, F., Harasym, T. O., Kadhim, S., Kowalski, R., Kultgen, S. G., Lee, A. C. H., Li, A. H., Majeski, S. A., Miller, A., Pasetka, C., Reid, S. P., Rijnbrand, R., Micolochick Steuer, H. M., Stever, K., Tang, S., Teng, X., Wang, X., & Sofia, M. J. (2021). Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral research, 197105211. https://doi.org/10.1016/j.antiviral.2021.105211
Mani, Nagraj, et al. "Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein." Antiviral research vol. 197 (2021): 105211. doi: https://doi.org/10.1016/j.antiviral.2021.105211
Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23. PMID: 34826506.
Copy Download .nbib Format: NLM
Time-Dependent Indirect Antioxidative Effects of Oat Beta-Glucans on Peripheral Blood Parameters in the Animal Model of Colon Inflammation.

Antioxidants (Basel, Switzerland)

Kopiasz Ł, Dziendzikowska K, Gajewska M, Wilczak J, Harasym J, Żyła E, Kamola D, Oczkowski M, Królikowski T, Gromadzka-Ostrowska J.
PMID: 32365955
Antioxidants (Basel). 2020 Apr 30;9(5). doi: 10.3390/antiox9050375.

No abstract available.

Cite
Kopiasz Ł, Dziendzikowska K, Gajewska M, et al. Time-Dependent Indirect Antioxidative Effects of Oat Beta-Glucans on Peripheral Blood Parameters in the Animal Model of Colon Inflammation. Antioxidants (Basel). 2020;9(5)doi: 10.3390/antiox9050375.
Kopiasz, �. �., Dziendzikowska, K., Gajewska, M., Wilczak, J., Harasym, J., Żyła, E., Kamola, D., Oczkowski, M., Królikowski, T., & Gromadzka-Ostrowska, J. (2020). Time-Dependent Indirect Antioxidative Effects of Oat Beta-Glucans on Peripheral Blood Parameters in the Animal Model of Colon Inflammation. Antioxidants (Basel, Switzerland), 9(5), . https://doi.org/10.3390/antiox9050375
Kopiasz, Łukasz, et al. "Time-Dependent Indirect Antioxidative Effects of Oat Beta-Glucans on Peripheral Blood Parameters in the Animal Model of Colon Inflammation." Antioxidants (Basel, Switzerland) vol. 9,5 (2020). doi: https://doi.org/10.3390/antiox9050375
Kopiasz Ł, Dziendzikowska K, Gajewska M, Wilczak J, Harasym J, Żyła E, Kamola D, Oczkowski M, Królikowski T, Gromadzka-Ostrowska J. Time-Dependent Indirect Antioxidative Effects of Oat Beta-Glucans on Peripheral Blood Parameters in the Animal Model of Colon Inflammation. Antioxidants (Basel). 2020 Apr 30;9(5). doi: 10.3390/antiox9050375. PMID: 32365955; PMCID: PMC7278816.
Copy Download .nbib Format: NLM
Neurocognitive Assessment Tools for Military Personnel With Mild Traumatic Brain Injury: Scoping Literature Review.

JMIR mental health

Jones C, Harasym J, Miguel-Cruz A, Chisholm S, Smith-MacDonald L, Brémault-Phillips S.
PMID: 33616538
JMIR Ment Health. 2021 Feb 22;8(2):e26360. doi: 10.2196/26360.

BACKGROUND: Mild traumatic brain injury (mTBI) occurs at a higher frequency among military personnel than among civilians. A common symptom of mTBIs is cognitive dysfunction. Health care professionals use neuropsychological assessments as part of a multidisciplinary and best practice...

Cite
Jones C, Harasym J, Miguel-Cruz A, et al. Neurocognitive Assessment Tools for Military Personnel With Mild Traumatic Brain Injury: Scoping Literature Review. JMIR Ment Health. 2021;8(2):e26360doi: 10.2196/26360.
Jones, C., Harasym, J., Miguel-Cruz, A., Chisholm, S., Smith-MacDonald, L., & Brémault-Phillips, S. (2021). Neurocognitive Assessment Tools for Military Personnel With Mild Traumatic Brain Injury: Scoping Literature Review. JMIR mental health, 8(2), e26360. https://doi.org/10.2196/26360
Jones, Chelsea, et al. "Neurocognitive Assessment Tools for Military Personnel With Mild Traumatic Brain Injury: Scoping Literature Review." JMIR mental health vol. 8,2 (2021): e26360. doi: https://doi.org/10.2196/26360
Jones C, Harasym J, Miguel-Cruz A, Chisholm S, Smith-MacDonald L, Brémault-Phillips S. Neurocognitive Assessment Tools for Military Personnel With Mild Traumatic Brain Injury: Scoping Literature Review. JMIR Ment Health. 2021 Feb 22;8(2):e26360. doi: 10.2196/26360. PMID: 33616538; PMCID: PMC7939942.
Copy Download .nbib Format: NLM
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.

Antiviral research

Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ.
PMID: 34826506
Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23.

AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC

Cite
Mani N, Cole AG, Phelps JR, et al. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021;197:105211doi: 10.1016/j.antiviral.2021.105211.
Mani, N., Cole, A. G., Phelps, J. R., Ardzinski, A., Burns, R., Chiu, T., Cuconati, A., Dorsey, B. D., Evangelista, E., Fan, K., Guo, F., Harasym, T. O., Kadhim, S., Kowalski, R., Kultgen, S. G., Lee, A. C. H., Li, A. H., Majeski, S. A., Miller, A., Pasetka, C., Reid, S. P., Rijnbrand, R., Micolochick Steuer, H. M., Stever, K., Tang, S., Teng, X., Wang, X., & Sofia, M. J. (2021). Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral research, 197105211. https://doi.org/10.1016/j.antiviral.2021.105211
Mani, Nagraj, et al. "Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein." Antiviral research vol. 197 (2021): 105211. doi: https://doi.org/10.1016/j.antiviral.2021.105211
Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23. PMID: 34826506.
Copy Download .nbib Format: NLM
Microwave radiation and protein addition modulate hydration, pasting and gel rheological characteristics of rice and potato starches.

Carbohydrate polymers

Villanueva M, De Lamo B, Harasym J, Ronda F.
PMID: 30241831
Carbohydr Polym. 2018 Dec 01;201:374-381. doi: 10.1016/j.carbpol.2018.08.052. Epub 2018 Aug 13.

This study evaluated for first time the effect of Microwave (MW) radiation on systems based on potato and rice starches supplemented with 5% of calcium caseinate (CA) or soy protein isolate (SPI). The goal of this treatment was the...

Cite
Villanueva M, De Lamo B, Harasym J, et al. Microwave radiation and protein addition modulate hydration, pasting and gel rheological characteristics of rice and potato starches. Carbohydr Polym. 2018;201:374-381doi: 10.1016/j.carbpol.2018.08.052.
Villanueva, M., De Lamo, B., Harasym, J., & Ronda, F. (2018). Microwave radiation and protein addition modulate hydration, pasting and gel rheological characteristics of rice and potato starches. Carbohydrate polymers, 201374-381. https://doi.org/10.1016/j.carbpol.2018.08.052
Villanueva, Marina, et al. "Microwave radiation and protein addition modulate hydration, pasting and gel rheological characteristics of rice and potato starches." Carbohydrate polymers vol. 201 (2018): 374-381. doi: https://doi.org/10.1016/j.carbpol.2018.08.052
Villanueva M, De Lamo B, Harasym J, Ronda F. Microwave radiation and protein addition modulate hydration, pasting and gel rheological characteristics of rice and potato starches. Carbohydr Polym. 2018 Dec 01;201:374-381. doi: 10.1016/j.carbpol.2018.08.052. Epub 2018 Aug 13. PMID: 30241831.
Copy Download .nbib Format: NLM
Antibody conjugation methods for active targeting of liposomes.

Methods in molecular medicine

Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB, Cullis PR.
PMID: 21318840
Methods Mol Med. 2000;25:51-68. doi: 10.1385/1-59259-075-6:51.

Liposomes are useful drug delivery vehicles since they may protect encapsulated drugs from enzymatic degradation and rapid clearance in vivo, or alter biodistribution, potentially leading to reduced toxicities (1,2). A major limitation to the development of many specialized applications...

Cite
Ansell SM, Harasym TO, Tardi PG, et al. Antibody conjugation methods for active targeting of liposomes. Methods Mol Med. 2000;25:51-68doi: 10.1385/1-59259-075-6:51.
Ansell, S. M., Harasym, T. O., Tardi, P. G., Buchkowsky, S. S., Bally, M. B., & Cullis, P. R. (2000). Antibody conjugation methods for active targeting of liposomes. Methods in molecular medicine, 2551-68. https://doi.org/10.1385/1-59259-075-6:51
Ansell, S M, et al. "Antibody conjugation methods for active targeting of liposomes." Methods in molecular medicine vol. 25 (2000): 51-68. doi: https://doi.org/10.1385/1-59259-075-6:51
Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB, Cullis PR. Antibody conjugation methods for active targeting of liposomes. Methods Mol Med. 2000;25:51-68. doi: 10.1385/1-59259-075-6:51. PMID: 21318840.
Copy Download .nbib Format: NLM
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.

Antiviral research

Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ.
PMID: 34826506
Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23.

AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC

Cite
Mani N, Cole AG, Phelps JR, et al. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021;197:105211doi: 10.1016/j.antiviral.2021.105211.
Mani, N., Cole, A. G., Phelps, J. R., Ardzinski, A., Burns, R., Chiu, T., Cuconati, A., Dorsey, B. D., Evangelista, E., Fan, K., Guo, F., Harasym, T. O., Kadhim, S., Kowalski, R., Kultgen, S. G., Lee, A. C. H., Li, A. H., Majeski, S. A., Miller, A., Pasetka, C., Reid, S. P., Rijnbrand, R., Micolochick Steuer, H. M., Stever, K., Tang, S., Teng, X., Wang, X., & Sofia, M. J. (2021). Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral research, 197105211. https://doi.org/10.1016/j.antiviral.2021.105211
Mani, Nagraj, et al. "Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein." Antiviral research vol. 197 (2021): 105211. doi: https://doi.org/10.1016/j.antiviral.2021.105211
Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23. PMID: 34826506.
Copy Download .nbib Format: NLM
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.

Antiviral research

Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ.
PMID: 34826506
Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23.

AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC

Cite
Mani N, Cole AG, Phelps JR, et al. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021;197:105211doi: 10.1016/j.antiviral.2021.105211.
Mani, N., Cole, A. G., Phelps, J. R., Ardzinski, A., Burns, R., Chiu, T., Cuconati, A., Dorsey, B. D., Evangelista, E., Fan, K., Guo, F., Harasym, T. O., Kadhim, S., Kowalski, R., Kultgen, S. G., Lee, A. C. H., Li, A. H., Majeski, S. A., Miller, A., Pasetka, C., Reid, S. P., Rijnbrand, R., Micolochick Steuer, H. M., Stever, K., Tang, S., Teng, X., Wang, X., & Sofia, M. J. (2021). Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral research, 197105211. https://doi.org/10.1016/j.antiviral.2021.105211
Mani, Nagraj, et al. "Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein." Antiviral research vol. 197 (2021): 105211. doi: https://doi.org/10.1016/j.antiviral.2021.105211
Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23. PMID: 34826506.
Copy Download .nbib Format: NLM
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.

Antiviral research

Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ.
PMID: 34826506
Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23.

AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC

Cite
Mani N, Cole AG, Phelps JR, et al. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021;197:105211doi: 10.1016/j.antiviral.2021.105211.
Mani, N., Cole, A. G., Phelps, J. R., Ardzinski, A., Burns, R., Chiu, T., Cuconati, A., Dorsey, B. D., Evangelista, E., Fan, K., Guo, F., Harasym, T. O., Kadhim, S., Kowalski, R., Kultgen, S. G., Lee, A. C. H., Li, A. H., Majeski, S. A., Miller, A., Pasetka, C., Reid, S. P., Rijnbrand, R., Micolochick Steuer, H. M., Stever, K., Tang, S., Teng, X., Wang, X., & Sofia, M. J. (2021). Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral research, 197105211. https://doi.org/10.1016/j.antiviral.2021.105211
Mani, Nagraj, et al. "Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein." Antiviral research vol. 197 (2021): 105211. doi: https://doi.org/10.1016/j.antiviral.2021.105211
Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23. PMID: 34826506.
Copy Download .nbib Format: NLM
Not an 'either/or': Integrating mental health and psychosocial support within non-communicable disease prevention and care in humanitarian response.

Journal of global health

Gyawali B, Harasym MC, Hassan S, Cooper K, Boschma A, Bird M, Konradsen F, Raju E, Tellier S.
PMID: 34804510
J Glob Health. 2021 Nov 13;11:03119. doi: 10.7189/jogh.11.03119. eCollection 2021.

No abstract available.

Cite
Gyawali B, Harasym MC, Hassan S, et al. Not an 'either/or': Integrating mental health and psychosocial support within non-communicable disease prevention and care in humanitarian response. J Glob Health. 2021;11:03119doi: 10.7189/jogh.11.03119.
Gyawali, B., Harasym, M. C., Hassan, S., Cooper, K., Boschma, A., Bird, M., Konradsen, F., Raju, E., & Tellier, S. (2021). Not an 'either/or': Integrating mental health and psychosocial support within non-communicable disease prevention and care in humanitarian response. Journal of global health, 1103119. https://doi.org/10.7189/jogh.11.03119
Gyawali, Bishal, et al. "Not an 'either/or': Integrating mental health and psychosocial support within non-communicable disease prevention and care in humanitarian response." Journal of global health vol. 11 (2021): 03119. doi: https://doi.org/10.7189/jogh.11.03119
Gyawali B, Harasym MC, Hassan S, Cooper K, Boschma A, Bird M, Konradsen F, Raju E, Tellier S. Not an 'either/or': Integrating mental health and psychosocial support within non-communicable disease prevention and care in humanitarian response. J Glob Health. 2021 Nov 13;11:03119. doi: 10.7189/jogh.11.03119. eCollection 2021. PMID: 34804510; PMCID: PMC8590828.
Copy Download .nbib Format: NLM
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.

Antiviral research

Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ.
PMID: 34826506
Antiviral Res. 2022 Jan;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23.

AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC

Cite
Mani N, Cole AG, Phelps JR, et al. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021;197:105211doi: 10.1016/j.antiviral.2021.105211.
Mani, N., Cole, A. G., Phelps, J. R., Ardzinski, A., Burns, R., Chiu, T., Cuconati, A., Dorsey, B. D., Evangelista, E., Fan, K., Guo, F., Harasym, T. O., Kadhim, S., Kowalski, R., Kultgen, S. G., Lee, A. C. H., Li, A. H., Majeski, S. A., Miller, A., Pasetka, C., Reid, S. P., Rijnbrand, R., Micolochick Steuer, H. M., Stever, K., Tang, S., Teng, X., Wang, X., & Sofia, M. J. (2022). Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral research, 197105211. https://doi.org/10.1016/j.antiviral.2021.105211
Mani, Nagraj, et al. "Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein." Antiviral research vol. 197 (2022): 105211. doi: https://doi.org/10.1016/j.antiviral.2021.105211
Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2022 Jan;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23. PMID: 34826506.
Copy Download .nbib Format: NLM
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.

Antiviral research

Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ.
PMID: 34826506
Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23.

AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC

Cite
Mani N, Cole AG, Phelps JR, et al. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021;197:105211doi: 10.1016/j.antiviral.2021.105211.
Mani, N., Cole, A. G., Phelps, J. R., Ardzinski, A., Burns, R., Chiu, T., Cuconati, A., Dorsey, B. D., Evangelista, E., Fan, K., Guo, F., Harasym, T. O., Kadhim, S., Kowalski, R., Kultgen, S. G., Lee, A. C. H., Li, A. H., Majeski, S. A., Miller, A., Pasetka, C., Reid, S. P., Rijnbrand, R., Micolochick Steuer, H. M., Stever, K., Tang, S., Teng, X., Wang, X., & Sofia, M. J. (2021). Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral research, 197105211. https://doi.org/10.1016/j.antiviral.2021.105211
Mani, Nagraj, et al. "Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein." Antiviral research vol. 197 (2021): 105211. doi: https://doi.org/10.1016/j.antiviral.2021.105211
Mani N, Cole AG, Phelps JR, Ardzinski A, Burns R, Chiu T, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Harasym TO, Kadhim S, Kowalski R, Kultgen SG, Lee ACH, Li AH, Majeski SA, Miller A, Pasetka C, Reid SP, Rijnbrand R, Micolochick Steuer HM, Stever K, Tang S, Teng X, Wang X, Sofia MJ. Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein. Antiviral Res. 2021 Nov 23;197:105211. doi: 10.1016/j.antiviral.2021.105211. Epub 2021 Nov 23. PMID: 34826506.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries